Patrys Ltd
ASX:PAB
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
AU |
Patrys Ltd
ASX:PAB
|
16.4m AUD | 0 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 9.2 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 11.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.1B USD | 11.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109B USD | 9 | ||
AU |
CSL Ltd
ASX:CSL
|
134.1B AUD | 13.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.4B USD | 4.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.2B USD | 40 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.9B USD | 5.3 | ||
KR |
Celltrion Inc
KRX:068270
|
38.6T KRW | 37.6 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.